Venetoclax (CAS 1257044-40-8) – Anticancer API

Venetoclax (CAS 1257044-40-8) is a high-potency selective BCL-2 inhibitor anticancer API, featuring a targeted mechanism that disrupts cancer cell survival pathways. Its molecular structure binds specifically to BCL-2 proteins, triggering mitochondrial apoptosis and eliminating malignant cells without harming normal tissues. Produced via advanced precision synthesis and GMP-compliant processes, it ensures ultra-high purity, consistent bioactivity, and adherence to global oncology drug standards.

This premium API is a cornerstone raw material for pharmaceutical manufacturers developing targeted hematological cancer therapies. It is widely applied in formulating drugs for chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and other blood cancers, especially for patients with relapsed or refractory conditions. With proven clinical efficacy in improving remission rates and prolonging survival, it addresses the urgent need for innovative cancer treatments. For R&D teams and production enterprises, it provides a trusted solution to advance precision oncology care.